This study represents a novel individualized therapeutic approach in brain metastases, a disease with a critical need for effective therapy. Support: U10CA180821, U10CA180882, https://acknowledgments.alliancefound.org; Genentech, Kazia Therapeutics Limited, Eli Lilly; Clinical trial information: NCT03994796.
We are the minno in with the big fish and PB has moved the goal post and given us the lion shares of the patients to boot.
Across the pond...Nasdaq: KZIA, page-159
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)